Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityActive in the last 2 years

Dongming Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1854-9531; OpenAlex author ID A5091221493. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper

Papers 12

  1. GPX3 represses pancreatic cancer cell proliferation, migration and invasion, and improves their chemo‑sensitivity by regulating the JNK/c‑Jun signaling pathway. Last author DOI 10.3892/etm.2024.12407↗
  2. Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α express… Last author DOI 10.1002/cbin.12074↗
  3. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-023-40727-7↗
  4. RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. Co-author DOI 10.1007/s13258-022-01217-0↗
  5. Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo. Co-author DOI 10.21037/tcr-20-2627↗
  6. Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.628346↗
  7. Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.682969↗
  8. A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.1002/prca.201800195↗
  9. DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Co-author PMID 31911850↗
  10. B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.20421↗
  11. Expression and clinical significance of glucose transporter-1 in pancreatic cancer. Co-author DOI 10.3892/ol.2016.4586↗
  12. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2015.06.074↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian Zhou · 6 shared papers, 2015–2022 · strength 0.56
  2. Ye Ma · 2 shared papers, 2023–2024 · strength 0.55
  3. Dechun Li · 5 shared papers, 2015–2022 · strength 0.52
  4. Xin Gao · 2 shared papers, 2021–2024 · strength 0.42
  5. Zixiang Zhang · 3 shared papers, 2019–2022 · strength 0.38
  6. Jian Yang · 3 shared papers, 2016–2022 · strength 0.31
  7. Yuchen Tang · 2 shared papers, 2021–2022 · strength 0.26
  8. Bin Yi · 2 shared papers, 2021–2022 · strength 0.26
  9. Yujie Huang · 2 shared papers, 2021–2022 · strength 0.26
  10. Ying Lv · 2 shared papers, 2021–2023 · strength 0.25
  11. Shu Zhang · 2 shared papers, 2021–2023 · strength 0.25
  12. Xiaoping Zou · 2 shared papers, 2021–2023 · strength 0.25
  13. Congyuan Zhu · 1 shared paper, 2023 · strength 0.24
  14. Hao Hu · 1 shared paper, 2023 · strength 0.24
  15. Jun Yao · 2 shared papers, 2019–2022 · strength 0.23
  16. Dongbao Li · 2 shared papers, 2017–2021 · strength 0.21
  17. Jian Yang · 2 shared papers, 2019 · strength 0.19
  18. Yi Zhang · 2 shared papers, 2015–2022 · strength 0.18
  19. Xin Zhao · 1 shared paper, 2021 · strength 0.15
  20. Tao Chen · 1 shared paper, 2021 · strength 0.15
  21. Lei Wang · 1 shared paper, 2023 · strength 0.14
  22. Yixuan Zhang · 1 shared paper, 2023 · strength 0.14
  23. Hao Wu · 1 shared paper, 2023 · strength 0.14
  24. Chao Yan · 1 shared paper, 2023 · strength 0.14
  25. Shanshan Shen · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.